

9<sup>th</sup> November 2021

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Update on the Definitive Agreement (“Agreement”) entered between Cipla Technologies LLC (“CipTec”) and Pulmatrix Inc. (“Pulmatrix”) for development and commercialization of Pulmazole**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to the intimations dated 15<sup>th</sup> April, 2019 and 13<sup>th</sup> July, 2020, we hereby notify that Cipla Technologies, LLC (“CipTec”), wholly owned step-down subsidiary of Cipla Limited and Pulmatrix Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, has completed an amendment to agreement for the development and commercialization of Pulmazole.

Pursuant to the 2<sup>nd</sup> amendment, CipTec will continue to reimburse Pulmatrix for 50% of all third-party costs for the development of Pulmazole in the following manner: (i) 40% of Pulmatrix dedicated personnel and consulting costs (“direct costs”) (ii) another 10% of Pulmatrix’s “direct costs” upon the timely achievement of certain development milestones. The development milestones for Pulmatrix’s planned Phase 2b clinical trial include the dosing of 25% of participants in the clinical trial by June 30, 2023, and the delivery of top-line data results to the joint steering committee for the program by June 30, 2024. If the development milestones are not achieved within 9-months of such dates either party may terminate its obligation to fund its share of development costs. Pulmatrix has also granted CipTec exclusive rights to the development and commercialization of Pulmazole in the “Cipla Territory” (India, Nepal, Yemen, Iran, South Africa, Sri Lanka, Myanmar and Algeria) in exchange for, under certain circumstances, 2% royalties on net sales of Pulmazole in the Cipla Territory.

This is for your information and records.

Kindly acknowledge the receipt.

Thankyou

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**  
Prepared by: Mandar Kurghode